Literature DB >> 21169528

Pax6 regulates proliferation and apoptosis of human retinoblastoma cells.

Shu-wei Bai1, Bin Li, Hao Zhang, Jost B Jonas, Bo-wen Zhao, Ling Shen, Yi-chen Wang.   

Abstract

PURPOSE: To assess whether the Pax6 gene is involved in the development of retinoblastoma.
METHODS: Three human retinoblastoma cell cultures were transfected with human Pax6 specific double-stranded, small interfering siRNA molecules RH-1 and RH-2. In addition, untreated control groups and negative control groups (CT groups) transfected with siRNA without homology to the human genome were formed for all three cell culture lines.
RESULTS: After Pax6 gene was silenced by siRNA, the percentage of tumor cell survival decreased significantly (P < 0.05). Correspondingly, the percentage of apoptotic cells to total cells was significantly (P < 0.05) higher in the three retinoblastoma cell lines transfected with siRNA than in the CT control groups and the untreated control groups. In a parallel manner, the cell cycle was significantly (P < 0.01) altered in the transfected study groups, with reduced percentages of retinoblastoma cells in the S-phase. The cell-cycle-associated protein P21 was upregulated, and the protein P27 was slightly upregulated in the transfected retinoblastoma cell lines, in comparison to the control groups.
CONCLUSIONS: Silencing the Pax6 gene with short interfering RNA resulted in an inhibited growth and an increased apoptosis of cultured human retinoblastoma cells. It was paralleled by upregulation of the P21 and P27 proteins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21169528     DOI: 10.1167/iovs.10-5487

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

1.  Pax6 expressed in osteocytes inhibits canonical Wnt signaling.

Authors:  Ajita Jami; Jogeswar Gadi; Min Jung Lee; Eun Jin Kim; Mi Jeong Lee; Han-Sung Jung; Hong-Hee Kim; Sung-Kil Lim
Journal:  Mol Cells       Date:  2013-03-22       Impact factor: 5.034

2.  Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.

Authors:  Xiangxian Zhang; Xiao Yang; Junling Wang; Tiansong Liang; Yue Gu; Daoke Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

3.  miR-488 acts as a tumor suppressor gene in gastric cancer.

Authors:  Yan Zhao; Guifang Lu; Xiquan Ke; Xinlan Lu; Xin Wang; Hongxia Li; Mudan Ren; Shuixiang He
Journal:  Tumour Biol       Date:  2016-01-06

4.  Interaction between Pax6 and its novel mutant in Bufo raddei Strauch.

Authors:  Furong Ju; Yongqing Zhao; Yuanlin Zhao; Ying Wang; Fan Wen; Lin Ye; Lan Gao
Journal:  Mol Vis       Date:  2011-10-18       Impact factor: 2.367

5.  PAX Genes in Cancer; Friends or Foes?

Authors:  Caiyun G Li; Michael R Eccles
Journal:  Front Genet       Date:  2012-01-31       Impact factor: 4.599

6.  Eye selector logic for a coordinated cell cycle exit.

Authors:  Carla S Lopes; Fernando Casares
Journal:  PLoS Genet       Date:  2015-02-19       Impact factor: 5.917

7.  The TF-miRNA Coregulation Network in Oral Lichen Planus.

Authors:  Yu-Ling Zuo; Di-Ping Gong; Bi-Ze Li; Juan Zhao; Ling-Yue Zhou; Fang-Yang Shao; Zhao Jin; Yuan He
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

8.  Downregulation of PAX6 by shRNA inhibits proliferation and cell cycle progression of human non-small cell lung cancer cell lines.

Authors:  Xiaoting Zhao; Wentao Yue; Lina Zhang; Li Ma; Wenyun Jia; Zhe Qian; Chunyan Zhang; Yue Wang
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

9.  Spatiotemporal Patterns of Tumor Occurrence in Children with Intraocular Retinoblastoma.

Authors:  Benjamin A King; Carlos Parra; Yimei Li; Kathleen J Helton; Ibrahim Qaddoumi; Matthew W Wilson; Robert J Ogg
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

10.  Suppression of PAX6 promotes cell proliferation and inhibits apoptosis in human retinoblastoma cells.

Authors:  Bo Meng; Yisong Wang; Bin Li
Journal:  Int J Mol Med       Date:  2014-06-17       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.